Evolving Care Strategies in Newly Diagnosed HL: Emerging Therapies and the Changing Role of the Oncology Nurse

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: December 06, 2018
Expiration Date: December 06, 2019

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

New and emerging therapies are changing the treatment paradigms and care of patients with newly diagnosed advanced Hodgkin lymphoma. This symposium replay takes a closer look at these changes and their impact to nursing care. Our presenters provide an overview of the therapeutic treatment options and their known side-effect profiles which, if left unmanaged, could impact the overall progress and quality of life for patients. This activity includes presentations from our expert faculty on best strategies to employ in recognizing, treating, and long-term management of adverse events. We encourage you to listen in as faculty discuss the day-to-day educational needs of patients being treated for cHL.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including oncology nurses and other allied healthcare professionals who provide care to patients with Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Outline potential treatment strategies for newly diagnosed Hodgkin lymphoma (HL) patients, identifying patient- and disease-related factors that should be considered in selecting the most appropriate therapy for each individual
  • Correlate efficacy and safety data of agents that have been recently approved for treatment of newly diagnosed HL patients with the most appropriate patient type for each
  • Describe the potential impact of treatment-related adverse events (AEs) in newly diagnosed HL patients, and outline proactive management strategies for monitoring and treating these AEs
  • Apply strategies for educating and communicating with newly diagnosed HL patients that will support improved patient-centric care and optimized outcomes

Agenda

Evolving Care Strategies in Newly Diagnosed HL: Emerging Therapies and the Changing Role of the Oncology Nurse – Amy Goodrich, RN, MSN, CRNP

Best Practice Management of Common Adverse Events – Mollie Moran, MSN, CNP, AOCNP

Instructions for Participation and Credit

This activity is eligible for credit through December 06, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Amy L. Goodrich, RN, MSN, CRNP
Nurse Practitioner
Hematologic Malignancies Program
The Sidney Kimmel Cancer Center at Johns Hopkins
Baltimore, Maryland

Amy Goodrich earned her master’s degree as an acute care nurse practitioner from the Johns Hopkins University and her undergraduate nursing degree from the University of Pittsburgh. She is a is a Nurse Practitioner in the Hematologic Malignancies Program at The Sidney Kimmel Cancer Center at Johns Hopkins in Baltimore, Maryland. Ms. Goodrich manages patients with various types of hematologic malignancies, concentrating on the lymphomas. She also manages the Cancer Center’s research nurses and is extremely involved in research operations. Ms. Goodrich has presented extensively on various hematologic malignancies, new agents, symptom management, and other topics important to oncology nursing.

Mollie E. Moran, MSN, CNP, AOCNP
Oncology Nurse Practitioner
Hematologic Malignancies Division
James Cancer Hospital and Solove Research Institute
The Ohio State University
Columbus, Ohio

Mollie Moran earned both her bachelor’s and master’s degrees from the University of Pennsylvania in Philadelphia where she was a staff nurse in leukemia and bone marrow transplant. She then went to Johns Hopkins in Baltimore where she was a Leukemia Nurse Practitioner. Ms. Moran currently works as a Nurse Practitioner in the Hematologic Malignancies Division at the James Cancer Hospital and Solove Research Institute at The Ohio State University in Columbus, Ohio. Her area of focus is lymphoma and chronic leukemia, and she has published and presented extensively on these subjects.

Accreditation

MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-044-089

Disclosures

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Amy Goodrich has disclosed no relevant financial relationships.

Mollie Moran has received honoraria related to formal advisory activities from AbbVie Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Seattle Genetics, Inc.

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

MediCom Worldwide, Inc. would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support. To better serve the needs of our audience, ManagingHodgkinLymphoma.com is now ManagingLymphoma.com

©2019 MediCom Worldwide, Inc. All rights reserved